# Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward Keystone,J. Loveless,Gerd‐Rüdiger Burmester,Matthew Cravets,E. Hessey,T Shaw,Mark C. Totoritis |
| Citations | 1,643 |
| DOI | 10.1002/art.22025 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2024644107 |
| PMID | 16947627 |
| Type | article |
| Year | 2006 |

## Paper authors

- [Richard Furie](https://scholariq.org/researchers/richard-furie/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.